Investigation of a new horizon antifungal activity with enhancing the antimicrobial efficacy of ciprofloxacin and its binary mixture via their encapsulation in nanoassemblies: in vitro and in vivo evaluation

• Published in: Drug development research Vol. 81; no. 3; pp. 374 - 388
• Main Authors: Abou Taleb, Sally, Darwish, Asmaa Badawy, Abood, Amira, Mohamed, Amany M.
• Format: Journal Article
• Language: English
• Published: Hoboken, USA John Wiley & Sons, Inc 01.05.2020; Wiley Subscription Services, Inc
• Subjects: Antibacterial activity; antibacterial efficacy; Antifungal activity; Antiinfectives and antibacterials; Binary mixtures; Carnosine; Ciprofloxacin; Crosslinking; Cyclodextrin; Cyclodextrins; Drug delivery; Encapsulation; Entrapment; Evaluation; Formulations; Fungicides; In vivo methods and tests; nanosponge; N‐acetyl carnosine; ocular; Polymers; Spectrophotometry; Ultrasonic testing; Ultrasound; N-acetyl carnosine; nanosponge; antifungal activity; antibacterial efficacy; ciprofloxacin; ocular
• ISSN: 0272-4391; 1098-2299
• DOI: 10.1002/ddr.21632

The main goal of this study was to prepare and evaluate nanosponges containing ciprofloxacin (CIP) or its binary mixture with N‐acetyl carnosine (NAC). Nanosponges were prepared by ultrasound‐assisted synthesis technique using hydroxypropyl βeta‐cyclodextrin (HPβ‐CD), as the polymer and diphenyl carbonate (DPC) as the crosslinker. Entrapment efficiency (EE%) of CIP or its binary mixture with NAC in nanosponges was deduced spectrophotometrically. Nanosponges were characterized using several methods. EE% of CIP or its binary mixture with NAC inside nanosponges ranged from 98.63 ± 3.1 to 100 ± 0.07%. Particle size of nanosponges ranged from 66.7 to 90.1 nm. Release of drugs from nanosponges was biphasic and the release pattern followed Korsmeyer–Peppas model. Ex vivo and in vivo studies results showed that the antibacterial effect was enhanced with encapsulation of drugs in the nanosponge system. Furthermore, a potent antifungal activity was obtained from all examined formulae against Candida albicans (10231). The study revealed that successful encapsulation of CIP or its binary mixture with NAC in nanosponge formulations has innovated a new promising therapeutic activity for both drugs.